Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, suggests a way forward: suppressing a protein called ZNF638 triggers an antiviral immune response, making immune checkpoint inhibitors more effective.
Leave A Comment